Update on ARV-110 for anyone looking for a trial with a new drug approach - first in class - fast tracked May 2019

[George71]

"Arvinas is currently evaluating ARV-110 in a Phase 1 study for men with castration-resistant metastatic prostate cancer (mCRPC) who have progressed on standards of care."

arvinas.com/pipeline-progra...

"In a patient-derived xenograft (PDX) model derived from a patient not treated with, but insensitive to enzalutamide, orally delivered ARV-110 significantly inhibited the growth of enzalutamide-insensitive tumors (tumor growth inhibition: 100%)."

they list the trial as NCT03888612

for those who are mCRPC and have progressed on standard of care therapies.

It may work for everyone upfront -- who can tell.

clinicaltrials.gov/ct2/resu...

[George71]

Contact: Mary Garfield 475-234-5736 [e-mail]

Contact: Jennifer Ranciato 475-234-5700 [e-mail]

[Magnus1964]

Thanks for sharing.

[George71 in reply to Magnus1964]

since 1992 ??? !!!!!!! you're the KING ! --- great inspiration for the rest of us.

[Fairwind]

The trouble with these phase 1 trials, they usually have only a few participants and are conducted at only a few locations..These factors can make participation difficult..They don't look at the drugs efficiency, except maybe by accident..

[j-o-h-n]

By George..... thank you....

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 09/03/2020 7:36 PM DST